Cancer NetworkOriginal article
<![CDATA[FDA Clears IND For UGN-501 in Non-Muscle Invasive Bladder Cancer]]>
Phase 1UGN-501Positive
AI Analysis
Summary
FDA cleared the IND application for UGN-501, an intravesical therapy for non-muscle invasive bladder cancer. A Phase 1 study evaluating safety, tolerability, and feasibility is expected to begin in Q4 2026.
Clinical Trial Data
Phase
1
Outcome Details
FDA cleared IND application
Importance:6/10
Sentiment:
0.70
IND clearancebladder cancerintravesical therapyphase 1
Read the original article
Published by Cancer Network on July 8, 2026 3:00 PM